Navigation Links
HRP Stabilizing Diluent (Phosphate Buffered) from ScyTek Laboratories

ProductsHRP Stabilizing Diluent (Phosphate Buffered) from ScyTek Laboratories
Company ScyTek Laboratories
Item HRP Stabilizing Diluent (Phosphate Buffered)
Price $1,591.00
Description This product has been developed to significantly increase the shelf life of diluted peroxidase labeled proteins. Stability is increased at room temperature storage conditions in addition to 2-8 centigrade. This product is subjected to 0.45 micron filtration, and contains no mercury or azide. This formulation insures consistently high levels of activity for both the enzyme and the antibody following long-term storage at final-use dilution. HRP Stabilizer greatly improves the signal to noise ratios which increases the immunoassay sensitivity and offers cleaner assays. This product has been chemically engineered to increase conjugate stability providing the customer a longer shelf life, resistance to various shipping conditions & storage temperatures and improved day to day assay precision.

This product is recommended to be used in conjunction with ScyTek's proprietary Coating Stabilizer, Blocking Buffer (Super Block), Washing solution, TMB and Stopping Solution. All of the ELISA products are available in bulk quantities, including custom lot sizes up to 5000 liters. ScyTek Laboratories, Inc. specializes in custom manufacturing, vialing, labeling and packaging. Call today for a quote 800-729-8350.

Info ScyTek LaboratoriesScyTek Laboratories
205 South 600 West
Logan, UT 84321
Customer Service: (800) 729-8350
Fax Number: (435) 755-0015
Web Site: http://www.scytek.com/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Peroxidase, Horseradish, Conjugate-Stabilizing Solution from Calbiochem
2. Alk-Phos Stabilizing Diluent from ScyTek Laboratories
3. Conjugate Stabilizing Diluent Alkaline Phosphatase from Meridian Life Science, Inc.
4. Alk-Phos Stabilizing Diluent from ScyTek Laboratories
5. Conjugate Stabilizing Diluent HRP from Meridian Life Science, Inc.
6. HRP Stabilizing Diluent (Phosphate Buffered) without BSA from ScyTek Laboratories
7. HRP Stabilizing Diluent (MOPS Buffered) from ScyTek Laboratories
8. HRP Stabilizing Diluent (Phosphate Buffered) without BSA from ScyTek Laboratories
9. HRP Stabilizing Diluent (Phosphate Buffered) from ScyTek Laboratories
10. ELISA Antibody Diluent-Rabbit Polyclonal from AbD Serotec
11. HRP Monoclonal-Goat Diluent - 5X Concentrate from BioFX Laboratories, Inc.
Pronase Reagent...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Antigen peptide transporter ... TAP2) (Peptide transporter PSF2) ... (PSF-2) (Peptide transporter involved ... [Source:Uniprot/SWISSPROT;Acc:Q03519] ...
Biology Products:
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... they develop, vertebrate embryos form vertebrae in a ... that this process of body segmentation is controlled ... oscillating activity of certain genes within embryonic cells. ... timing system works. A new international ...
... Ind. -- Scientists at Indiana University and international collaborators ... a single molecule, producing a more effective therapy with ... obesity and related medical conditions. , The studies were ... Standiford H. Cox Distinguished Professor of Chemistry and the ...
... A new study demonstrates the dynamic role cilia play ... brain. Cilia are tiny hair-like structures on the surfaces ... radio antennae. In developing mouse embryos, researchers were ... migrate. The cilia appear to be receiving signals needed ...
Cached Biology News:Study sheds light on genetic 'clock' in embryonic cells 2Hormone combination effective and safe for treating obesity in mice 2Cilia guide neuronal migration in developing brain 2
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8